March 20, 2014 | Israeli biotech startup Gamida Cell, which develops stem-cell based therapies, is reportedly in advanced acquisition talks at a company value of $600 million. The Times of Israel reports that the company has received a large buy-out offer from an international pharmaceutical company.
Related posts
Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024
TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024
Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024
BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments